About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

PET-CT Predicting Lymph Nodes Metastasis

NCT05970913·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Fudan University

Age

20–80

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Solitary tumor, or multiple tumors with only ground-glass nodules (GGNs) apart from the primary lesion.
Diameter of the primary lesion ≤5cm, with a CTR between 0.5 and 1.
Pathological confirmation of non-small cell lung cancer (NSCLC) either before or during surgery.
No prior radiotherapy or chemotherapy for initial treatment.
No history of malignant tumors.

You may not be if

Locally advanced or distant metastasis.
Pleural dissemination observed during surgery.
History of malignant tumors.
Received neoadjuvant therapy.
Histopathological examination reveals lung malignancies other than non-small cell lung cancer (NSCLC).

The record

StatusActive not recruiting

PhaseNo phase

Taking part280

StartedNov 2023

UpdatedMar 23, 2026

Conditions

Non Small Cell Lung Cancer Lymph Node Metastasis Positron Emission Tomography

Where1

Shanghai Cancer Center
Shanghai, China

Clareo Health | PET-CT Predicting Lymph Nodes Metastasis